BRUKINSA® (zanubrutinib) capsules, for oral use: Clinical Monograph

Publication
Article
SupplementsBRUKINSA® (zanubrutinib) capsules, for oral use: Clinical Monograph

BRUKINSA® (zanubrutinib) capsules, for oral use: Clinical Monograph

Download Issue PDFDownload PDF
Articles in this issue
BRUKINSA® (zanubrutinib) capsules, for oral use: Clinical Monograph
Related Videos
Young depressed woman talking to lady psychologist during session, mental health - Image credit: motortion | stock.adobe.com
man taking opioid pills sitting at a dark table - Image credit: rohane | stock.adobe.com
schizophrenic man - mental disorder - Image credit: Andreza | stock.adobe.com
Aimee Keegan, PharmD, BCOP, a clinical pharmacist
A panel of 3 experts on hepatic encephalopathy
A panel of 3 experts on hepatic encephalopathy
Related Content
Patient receiving a vaccine -- Image credit: cherryandbees | stock.adobe.com

Recombinant Zoster Vaccine Demonstrates High Protection Against Shingles in Adult Patients

April 24th 2024
Article
Pharmacy Focus: Policy Edition - Discussing the DRUG Act and PBM Reform

Pharmacy Focus: Policy Edition - Discussing the DRUG Act and PBM Reform

April 5th 2024
Podcast
Question mark made by white pills spilling out of brown glass bottle on pink background. Creative medicine for health/medical problem, drug interaction, medication error and pharmaceutical concept - Image credit: Orawan | stock.adobe.com

Accurate, Complete Data Entry Is Key to Medication Safety

April 24th 2024
Article
Pharmacy Focus: OTC Contraception and Reproductive Health

Pharmacy Focus: OTC Contraception and Reproductive Health

March 29th 2024
Podcast
FDA approval stamp -- Image credit: Olivier Le Moal | stock.adobe.com

FDA Approves Lutathera for Pediatric Patients With SSTR+ Gastroenteropancreatic Neuroendocrine Tumors

April 23rd 2024
Article
Bladder Cancer | Image Credit: freshidea - stock.adobe.com

FDA Approves Anktiva Plus Bacillus Calmette-Guérin For Non-Muscle Invasive Bladder Cancer

April 23rd 2024
Article
© 2024 MJH Life Sciences

All rights reserved.